Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 37 for “"human epidermal growth factor receptor 2"”.
-
Molecular Mechanisms for the Angiotensin-(1-7)-Mediated Inhibition of Metastatic Triple Negative Breast Cancer
… triple negative, wherein tumors lack estrogen receptor and progesterone receptor expression and possess unamplified human epidermal growth factor receptor 2 (HER2) levels, contributing to an absence of effective, targeted therapeutics. Furthermore, triple negative breast cancer (TNBC) is …
-
New phytopharmaceutical anti-breast cancer formulations: immunoliposomes containing extra virgin olive oil polyphenols
… of these compounds. Trastuzumab targets the human epidermal growth factor receptor 2 (HER2), which is overexpressed in 20-30% of breast cancers. Using two breast cancer cell lines, with different HER2 expression levels, liposome and immunoliposomes decreased cancer cells viability in a …
-
REGULATION OF C-MET RECEPTOR TYROSINE KINASE SIGNALING BY ANGIOTENSIN-(1-7) IN TRIPLE NEGATIVE BREAST CANCER
… by the lack of estrogen and progesterone receptors as well as normal expression of the human epidermal growth factor receptor 2 (HER2). These cellular properties thereby exclude patients diagnosed with TNBC from the benefits of current targeted agents. The aggressive nature of TNBC coupled …
-
Investigation of the anti-cancer effects of rosemary (Rosmarinus Officinalis L.) extract in human breast and prostate cancer cells
… cancer (TNBC) cells do not express estrogen receptor, progesterone receptor, and human epidermal growth factor receptor-2 (HER-2). TNBC accounts for 15% of all breast cancer cases, is aggressive in nature, and is characterized by resistance to chemo and radiotherapy thus, finding new …
-
Sphingosine Kinase 1 Regulates Fascin Expression to Promote Metastasis In Triple Negative Breast Cancer
… or targeted therapies, as they lack estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2. Thus, understanding the signaling pathways that promote TNBC metastasis and developing novel therapeutic approaches to target them are critical, in order to prolong the …
-
Metabolic vulnerability in HER2-positive Breast Cancer
<p>The human epidermal growth factor receptor 2, or HER2, is overexpressed in 20-30% breast cancer patients and is associated with aggressive disease. Therapies targeting HER2, including monoclonal antibodies (trastuzumab and pertuzumab), a small molecule kinase inhibitor (lapatinib) and an …
-
Characterisation of cytokine secretion in malignant gliomas
… groups. These were follistatin, fibroblast growth factor (FGF), granulocyte – colony stimulating factor (G-CSF), soluble human epidermal growth factor receptor 2 neural (sHER2neu), soluble interleukin-6 receptor alpha (sIL-6R alpha), platelet-derived growth factor - AABB (PDGF-AABB), …
-
Use of Kinase Inhibitors to Illuminate Signaling Pathways in Breast Cancer
… 25-30% of diagnoses present themselves as human epidermal growth factor receptor 2 positive (HER-2+). HER-2 is a protein receptor located on the cell surface that interacts with other proteins and signaling molecules to translate extracellular signals into cellular process such as cell …
-
Targeting the actin cytoskeleton in HER2+ metastatic cancer cells using a macrolide toxin
… a subset of these cancers, dysregulation of the human epidermal growth factor receptor 2 (HER2) leads to overexpression of the receptor on the cell surface. Previous studies have found that these HER2+ cancers show high rates of progression to metastatic disease. Metastasis is driven by …
-
The Use of Catalytically Dead Cas9 to Identify Key Transcription Regulators in Triple Negative Breast Cancer
… Lack of expression of oestrogen, progesterone receptors, and human epidermal growth factor receptor 2 make TNBC patients ineligible to hormonal therapy. For these reasons the identification of novel clinical targets still remains a priority. With the advances of multiomics, many of the genes …
-
Dual mTOR/HDAC Inhibition: Preclinical Development of a Novel Breast Cancer Therapy
<p>HER2 (human epidermal growth factor receptor-2) and/or estrogen receptor (ER) are overexpressed in ~80% of human breast cancers. Although modern therapeutics (e.g. Trastuzumab, Tamoxifen) target the HER2 and ER receptors, clinical resistance often develops due to activation of downstream …
-
Validation of an aASPH-SNAP-tag fusion protein for immunodiagnosis of triple-negative breast cancer
… commonly known breast cancer markers such as human epidermal growth factor receptor 2 (HER2), estrogen(ER) and progesterone (PR). This subtype was also found to have a 2-fold higher increased risk in individuals with African ancestry, intensifying the African breast cancer burden. Currently …
-
Self-assembled Polymeric Nanoparticles for Targeted Delivery of Anticancer Drugs
… specific cell types exclusively through ligand-receptor interactions. The main goal of the project is to create a polymeric nanoparticle drug delivery system from synthesized biodegradable polymers and modify the polymeric nanoparticles using targeting antibodies for targeted delivery of …
-
Combined Inhibition of Ddr1 and Cdk4/6 Induces Synergistic Effects In Er-Positive, Her2-Negative Breast Cancer With Pik3Ca/Akt1 Mutations
… signaling pathway occur frequently in estrogen receptor–positive (ER-positive) breast tumors. Patients with ER-positive, human epidermal growth factor receptor 2–negative (HER2-negative) metastatic breast cancer are often treated with cyclin-dependent kinase (CDK4/6) inhibitors such as …
-
Novel Therapeutic Targets Identified By High-Throughput Technologies For Triple-Negative Breast Cancer
… expression of the estrogen and progesterone receptors, and normal expression of the human epidermal growth factor receptor 2. The lack of a well-characterized target for treatment leaves only systemic chemotherapy as the mainstay of treatment. Approximately 60-70% of patients are …
-
Modern Staging in Primary Breast Cancer-aspects of micrometastatic disease in bone marrow and molecular profiles in lymph node metastases
… nature of bone marrow biopsies. Oestrogen receptors (ER), progesterone receptors (PR), Ki67 and human epidermal growth factor receptor 2 (HER2) were compared in primary breast cancer tumours and the synchronous lymph node metastases (Papers II and IV) and primary tumours and relapses (Paper …
-
Interaction Between Brk and Her2 In Breast Cancer
… M.D.</p> <p>Breast tumor kinase (Brk) is a nonreceptor protein-tyrosine kinase that is highly expressed in approximately two thirds of breast cancers but is not detectable or is expressed at very low levels in normal mammary epithelium. Brk plays important roles in promoting proliferation, …
-
Roles of CCN5 in regulating progression and therapeutic sensitivity of breast cancer
… the cancer cells do not express nuclear hormone receptors and human epidermal growth factor receptor 2 (HER2), have worse survival rate compared to the patients with luminal subtypes of cancer. Here, we have shown that Cysteine-rich 61-Connective Tissue Growth Factor-nephroblastoma-overexpressed …
-
Antibody engineering to evaluate binding, internalisation, and intracellular routing of tumour-targeting fusion proteins
… of specific therapeutic markers such as estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). Current treatments primarily involve chemotherapy, radiotherapy, and surgery, as targeted therapies are limited. TNBC also exhibits significant …
-
Development of potential immunodiagnostic & therapeutic techniques using SNAP-fusion proteins as tools for the validation of Triple-negative Breast Cancer
… cancers that lack the expression of Progesterone receptor (PR), Estrogen receptor (ER) and Human epidermal growth factor receptor 2 (HER2). TNBC is commonly associated with early stage metastasis with low survival rates as well as a high frequency of recurrence and proves to be problematic in both …
Page 1 of 2